Pere Barba Archives

Pere Barba Receives the II FERO-Carmen Mateu Fellowship to Develop a New Generation of More Precise CAR-T Therapies for Acute Leukemias

On June 8, the FERO Gala brought together researchers, physicians, companies, philanthropists, and representatives of civil society in Barcelona who…

ASH 2025: safety and efficacy data from a phase 1 study show promise of next-generation CAR-T cell therapy in patients with refractory B-cell acute lymphoblastic leukemia

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy…

Vall d’Hebron shows long-term safety of CAR-T therapy in aggressive lymphoma patients

The results show the need for continuous monitoring of patients to detect and manage possible adverse effects occurring months and…

Treatment with bendamustine prior to CAR T-cell therapy in patients with refractory large B-cell lymphoma associates with poorer treatment outcomes

Led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Experimental Hematology Group and the Advanced Therapies Program of…

Novel platform shows preclinical and early clinical promise in accelerating the production of more effective CAR-T cell therapy

Co-authored by Pere Barba, a Lead Investigator of VHIO’s Experimental Hematology Group, results of a study published in Cancer Discovery…

Dr. Pere Barba, Dra. Mònica Linares i Dra. Josefina Cortés amb una pacient amb lupus

Vall d’Hebron includes its first patient in a pioneering study into the use of CAR T-cell therapy for lupus

CAR T-cell therapy consists of targeted immune system cell modification to attack the cells that produce the antibodies causing the…